Scarica l'app Stockscreener
4.51
4.16%
0.18
Pre-mercato:
4.64
0.13
+2.88%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
TradingKey - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055 - TradingKey
ZNTL Initiated Coverage by Rodman & Renshaw -- Price Target Anno - GuruFocus
Rodman & Renshaw initiates Zentalis stock with buy on drug potential - Investing.com Canada
Zentalis Pharmaceuticals Inc (ZNTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
What date does Zentalis Pharmaceuticals's (ZNTL) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL) - The Globe and Mail
Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo
Mizuho Securities Initiates Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Announces Target Price $8 - Moomoo
Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin - Benzinga
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform By Investing.com - Investing.com South Africa
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform - Investing.com
ZNTL Initiates Coverage On by Mizuho -- Rating Set to Outperform - GuruFocus
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech - Ad-hoc-news.de
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance - ad-hoc-news.de
ZNTL Q1 2026 Earnings: Slightly Wider Loss Meets Modest Stock UptickEarnings Quality Score - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Zentalis Pharmaceuticals (ZNTL) Rallies 5.21% as Biotech Sector Finds FootingScalping Stock Signals - dars.gov.et
Zentalis Pharmaceuticals Surges 14%: Biotech Stock Breaks Above Key Support ZoneBearish Pattern Stocks - dars.gov.et
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2000 Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000E Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2500 Value Benchmark - marketscreener.com
ZNTL Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Remains in FocusCost Structure Review - DonanımHaber
Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL) - TradingView
Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals Inc (ZNTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zentalis Pharmaceuticals (ZNTL) Edges Higher as Biotech Sector Sees Mixed SentimentDividend Arbitrage - dars.gov.et
ZNTL Should I Buy - Intellectia AI
Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan
Zentalis Pharmaceuticals Inc (ZNTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):